Indo-Bangla Pharmaceuticals (DHA:IBP) 5-Year Yield-on-Cost %: 0.08 (As of Jul. 12, 2026)


DHA:IBP Indo-Bangla Pharmaceuticals Ltd DHA:IBP
32 GF Score
Price BDT18.40
View Full Analysis

What is Indo-Bangla Pharmaceuticals 5-Year Yield-on-Cost %?

Indo-Bangla Pharmaceuticals DHA:IBP +5.14% 32 5-Year Yield-on-Cost % is 0.08 as of Jul. 12, 2026. GuruFocus rates DHA:IBP with a GF Score™ of 32/100. Among 516 Drug Manufacturers companies, Indo-Bangla Pharmaceuticals ranks worse than 97.29% on this metric.

Indo-Bangla Pharmaceuticals's yield on cost for the quarter that ended in . 20 was 0.08.


The historical rank and industry rank for Indo-Bangla Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:

DHA:IBP' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.13
Current: 0.08

During the past 0 years, Indo-Bangla Pharmaceuticals's highest Yield on Cost was 0.13. The lowest was 0.00. And the median was 0.00.


DHA:IBP's 5-Year Yield-on-Cost % is ranked worse than
97.29% of 516 companies
in the Drug Manufacturers industry
Industry Median: 2.205 vs DHA:IBP: 0.08

Indo-Bangla Pharmaceuticals  (DHA:IBP) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Indo-Bangla Pharmaceuticals 5-Year Yield-on-Cost % Related Terms

DHA:IBP vs : 5-Year Yield-on-Cost % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Indo-Bangla Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Indo-Bangla Pharmaceuticals 5-Year Yield-on-Cost % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Indo-Bangla Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Indo-Bangla Pharmaceuticals's 5-Year Yield-on-Cost % falls into.


DHA:IBP
32GF Score
Indo-Bangla Pharmaceuticals Ltd DHA:IBP
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Indo-Bangla Pharmaceuticals 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Indo-Bangla Pharmaceuticals is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.08 mean?
Indo-Bangla Pharmaceuticals (DHA:IBP) has a 5-Year Yield-on-Cost % of 0.08 as of Jul. 12, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Indo-Bangla Pharmaceuticals and its competitors. According to the industry distribution chart, Indo-Bangla Pharmaceuticals ranks #502 out of 516 companies in the Drug Manufacturers industry, placing it in the top 97.3%.
Is Indo-Bangla Pharmaceuticals' 5-Year Yield-on-Cost % too high?
Indo-Bangla Pharmaceuticals' current 5-Year Yield-on-Cost % is 0.08. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.21. Indo-Bangla Pharmaceuticals' value of 0.08 is 96.4% below this industry median. Based on the distribution chart, Indo-Bangla Pharmaceuticals ranks #502 out of 516 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Indo-Bangla Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Indo-Bangla Pharmaceuticals' 5-Year Yield-on-Cost % compare to ?
According to the Drug Manufacturers industry distribution chart, Indo-Bangla Pharmaceuticals ranks #502 out of 516 companies for 5-Year Yield-on-Cost %. This places Indo-Bangla Pharmaceuticals in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.21. Indo-Bangla Pharmaceuticals' value of 0.08 is 96.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.21, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Indo-Bangla Pharmaceuticals's current 5-Year Yield-on-Cost % of 0.08 is 96.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Indo-Bangla Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indo-Bangla Pharmaceuticals's current 5-Year Yield-on-Cost % is 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indo-Bangla Pharmaceuticals stock overvalued right now?
Indo-Bangla Pharmaceuticals (DHA:IBP) has a current 5-Year Yield-on-Cost % of 0.08. The current 5-Year Yield-on-Cost % is 0.08 and 96.4% below the Drug Manufacturers industry median of 2.21. Indo-Bangla Pharmaceuticals' overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Indo-Bangla Pharmaceuticals (DHA:IBP), the current 5-Year Yield-on-Cost % is 0.08 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Indo-Bangla Pharmaceuticals Business Description

Comparable Companies
Address Ahmed Akbar Sobhan Road, Block B, Plot No. 183, 6th Floor, Bashundhara R/A, Baridhara, Dhaka, BGD, 1229
Indo-Bangla Pharmaceuticals Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products. The products of the company include human drugs dosages form such as tablets, capsules, syrup, oral saline, and suspension. The products of the company are sold in the domestic market.
32GF Score

Get the complete analysis for DHA:IBP

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT18.40
Price